Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 9 Central Nervous System Neoplasms 6 Brain Neoplasms 6 Oligodendroglioma 3 Gliosarcoma 3 Astrocytoma 3 Sarcoma 2 Optic Nerve Glioma 2 Neoplasm Metastasis 2 Glioma 2 Ependymoma 2 Zollinger-Ellison Syndrome 1 Wilms Tumor 1 Vipoma 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Somatostatinoma 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Retinoblastoma 1 Recurrence 1 Prolactinoma 1 Pituitary Neoplasms 1 Pheochromocytoma 1 Ovarian Neoplasms 1 Osteosarcoma 1 Non functioning pancreatic endocrine tumor 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors 1 Neuroblastoma 1 Multiple Endocrine Neoplasia Type 2b 1

Interventions

Gemcitabine 3 Cisplatin 3 Irinotecan 2 Fluorouracil 2 Capecitabine 2 tremelimumab 1 pamiparib 1 durvalumab 1 brigimadlin 1 atezolizumab 1 Temozolomide 1 Surgical Procedures, Operative 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 IMC-001 1 Blood Specimen Collection 1 ARX788 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Biliary Tract Neoplasms × Temozolomide × Clear all

NCT04796454 2022-06-01

PAMICC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡